The New England Journal of Medicine says that the maker of, Vioxx, Merck may have ommitted key data in research that is submitted to the journal to be published. The pharmaceutical company ommitted deaths that were attributed to the drug. Some financial analysts expect that Merck will have to increase the amount of money dedicated to dealing with this issue. Currently the company has approximately $17B but that amount is likely to get substantially higher.
No comments:
Post a Comment